Forward catalyst · ARGX

efgartigimod

Sponsor Argenx SE · listed as ARGX

READOUT Phase 2;Phase 3 Confidence: medium Source: clinicaltrials

efgartigimod is a clinical-stage drug asset sponsored by Argenx SE, listed as ARGX. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Mar 2027 (month precision, medium confidence), tied to trial NCT04833894. The asset is in Phase 2;Phase 3 and currently recruiting, studied in Generalized Myasthenia Gravis. It appears across 3 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-03-31

As disclosedMar 2027

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT04833894

PhasePHASE2;PHASE3

StatusRECRUITING

Lead sponsorargenx

Listed asARGX

Condition(s)Generalized Myasthenia Gravis

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More ARGX catalysts